• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII.

作者信息

Tokgoz H, Caliskan U, Lavigne-Lissalde G, Giansily-Blaizot M

出版信息

Haemophilia. 2012 Jan;18(1):e25-7. doi: 10.1111/j.1365-2516.2011.02666.x. Epub 2011 Oct 4.

DOI:10.1111/j.1365-2516.2011.02666.x
PMID:21973016
Abstract
摘要

相似文献

1
Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII.重组活化凝血因子VII（rFVIIa）在一名先天性凝血因子VII缺乏且伴有凝血因子VII抑制物的患者中的成功预防性应用。
Haemophilia. 2012 Jan;18(1):e25-7. doi: 10.1111/j.1365-2516.2011.02666.x. Epub 2011 Oct 4.
2
Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.因子 VII 缺乏症出血发作的替代治疗。前瞻性评估。
Thromb Haemost. 2013 Feb;109(2):238-47. doi: 10.1160/TH12-07-0476. Epub 2012 Dec 13.
3
Asymptomatic intracranial hemorrhage in a newborn with congenital factor VII deficiency and successful treatment with recombinant activated factor VII.一名患有先天性因子VII缺乏症的新生儿出现无症状颅内出血，经重组活化因子VII成功治疗。
Turk J Pediatr. 2018;60(5):562-565. doi: 10.24953/turkjped.2018.05.014.
4
Prophylaxis with recombinant-activated factor VII (rFVIIa) for minimally invasive surgery in a patient with congenital factor VII deficiency: a case report with a single-low dose of rFVIIa.先天性因子VII缺乏患者接受重组活化因子VII（rFVIIa）预防微创外科手术：单低剂量rFVIIa的病例报告
Blood Coagul Fibrinolysis. 2008 Oct;19(7):693-5. doi: 10.1097/MBC.0b013e3282f544ff.
5
A new report of FVII-inhibitor in a patient suffering from severe congenital FVII deficiency.一名患有严重先天性FVII缺乏症患者的FVII抑制剂新报告。
Haemophilia. 2015 Jul;21(4):e336-8. doi: 10.1111/hae.12708. Epub 2015 May 8.
6
Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.重组凝血因子VIIa在遗传性凝血因子VII缺乏症中的药代动力学特性表现为稳态时分布容积大且药效学作用持续时间延长。
Thromb Haemost. 2014 Aug;112(2):424-5. doi: 10.1160/TH13-12-1045. Epub 2014 Apr 24.
7
Successful control of central nervous system bleeding in two newborns with severe factor VII deficiency using rFVIIa administered via Port-a-Cath.通过植入式静脉输液港给予重组活化凝血因子VII成功控制两名严重凝血因子VII缺乏新生儿的中枢神经系统出血。
Semin Hematol. 2008 Apr;45(2 Suppl 1):S74. doi: 10.1053/j.seminhematol.2008.03.010.
8
Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII.重组凝血因子VIIa持续输注用于VII因子缺乏患者的手术治疗。
Thromb Haemost. 2005 Dec;94(6):1177-80. doi: 10.1160/TH05-05-0342.
9
A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency.
Clin Appl Thromb Hemost. 2015 Nov;21(8):724-8. doi: 10.1177/1076029614522545. Epub 2014 Mar 19.
10
Secondary prophylaxis with rFVIIa in hemophilia and inhibitors: recommendations from an experts committee from Argentina.
Medicina (B Aires). 2010;70(3):209-14.

引用本文的文献

1
Inhibitor in Congenital Factor VII Deficiency; a Rare but Serious Therapeutic Challenge-A Systematic Literature Review.先天性因子VII缺乏症中的抑制剂；一种罕见但严峻的治疗挑战——一项系统文献综述
J Clin Med. 2021 Jan 8;10(2):211. doi: 10.3390/jcm10020211.
2
Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII.使用腺相关病毒介导的酶原FVII表达持续纠正犬因子VII缺乏症。
Blood. 2016 Feb 4;127(5):565-71. doi: 10.1182/blood-2015-09-671420. Epub 2015 Dec 23.
3
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®)).
新诊断的先天性因子VII缺乏症及重组活化因子VII（诺其®）的应用
Clin Pharmacol. 2013;5:53-8. doi: 10.2147/CPAA.S39772. Epub 2013 Mar 15.
4
Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).先天性因子 VII 缺乏症的预防：适应证、疗效和安全性。来自 Seven Treatment Evaluation Registry (STER) 的结果。
Haematologica. 2013 Apr;98(4):538-44. doi: 10.3324/haematol.2012.074039. Epub 2013 Feb 12.